1. P87 Mesenchymal splice isoform fibroblast growth factor receptor (FGFR2c) is an independent prognostic biomarker and further refines risk stratification within endometrial cancer molecular subtypes. (1st November 2019) Authors: Sengal, A; Williams, E; McAlpine, J; Pollock, P Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. (1st November 2019) Authors: Leon-Castillo, A; de Boer, SM; Powell, ME; Mileshkin, LR; Mackay, HJ; Leary, A; Nijman, HW; Singh, N; Pollock, P; Bessette, P; Haie-Meder, C; Smit, VTHBM; Edmondson, RJ; Putter, H; Kitchener, HC; Crosbie, EJ; de Bruyn, M; Nout, RA; Horeweg, N; Bosse, T Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗